Semaglutide dampens residual inflammation in individuals with type 2 diabetes: preliminary results from the DOTAFLAME study
May 28, 2024 | Young fellows session, 92nd EAS Congress 2024
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.